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Objectives This study sought to determine the pharmacodynamic effect of modulation of volume status by withdrawal and
reinstitution of diuretic treatment on markers of renal and tubular function.
Background Decreased renal perfusion and increased congestion are associated with renal dysfunction in patients with
heart failure.
Methods In this study, 30 patients with chronic systolic heart failure in a presumed euvolemic state and on standard oral
furosemide therapy (40 to 80 mg) were examined. At baseline, subjects were withdrawn from their loop diuret-
ics. After 72 h, their furosemide regimen was reinstated, and patients were studied again 3 days later. Serum
creatinine, atrial and B-type natriuretic peptide, urinary kidney injury molecule (KIM)-1, urinary N-acetyl-beta-D-
glucosaminidase (NAG), and serum as well as urinary neutrophil gelatinase–associated lipocalin (NGAL) were
determined at various time points.
Results Diuretic withdrawal resulted in increases in atrial and B-type natriuretic peptide (both p  0.05). Serum creatinine
was unaffected. Both urinary KIM-1 (p  0.001) and NAG (p  0.010) concentrations rose significantly, after diuretic
withdrawal, whereas serum and urinary NGAL were not significantly affected. After reinitiation of furosemide, both
urinary KIM-1 and NAG concentrations returned to baseline (both p  0.05), but NGAL values were unaffected.
Conclusions Subclinical changes in volume status by diuretic withdrawal and reinstitution are associated with increases and
decreases of markers of tubular dysfunction in stable heart failure. Diuretic therapy may favorably affect renal
and tubular function by decreasing congestion. (J Am Coll Cardiol 2011;57:2233–41) © 2011 by the American
College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.10.065Impaired renal function is one of the most important
prognostic factors in both acute and chronic systolic heart
failure (HF) (1,2). When reduced renal function is present
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accepted October 28, 2010.or worsening renal function occurs, prognosis in patients
with HF is extremely poor (1,3,4). Renal impairment in
systolic chronic HF is mainly linked with reduced renal
perfusion and systemic arterial pressure. In particular, in
situations of already reduced renal perfusion, venous con-
gestion, as shown by a high central venous pressure (CVP),
is independently associated with renal function (5–7). Di-
uretics are important drugs in patients with systolic HF
because they may control volume status by reducing extra-
See page 2242
cellular body water (8). However, these drugs can result in
volume depletion, thereby leading to renal dysfunction and
suboptimal cardiac loading, and may be associated with
reduced survival (9). On the other hand, they may also
reduce venous congestion, which might theoretically im-
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Volume Status, Diuretics, and Tubular Function May 31, 2011:2233–41prove renal function. So far it has
not been documented whether
modulating renal venous con-
gestion (or CVP) by diuretics
has beneficial effects on renal
function (6).
In the present study, we there-
fore set out to investigate the
impact of subtle changes in vol-
ume status on parameters of re-
nal clearance and tubular func-
tion in patients with chronic
systolic HF using a model of
staged diuretic withdrawal and
reinitiation. Because serum creati-
nine is not a very sensitive marker
to detect such changes, we inves-
tigated new biomarkers of tubular
function that may be more sensi-
tive to subtle changes (10).
Methods
Study population. Patients were
recruited from the Heart Failure Services at City and
Sandwell Hospitals, both in Birmingham, United King-
dom. Patients had to have a left ventricular ejection
fraction of 40% (on quantitative echocardiography or
rest radionucleotide scintigraphy) and were symptomatic
but clinically stable on chronic oral furosemide dosing (40 to
80 mg daily). Patients also had to be on optimal (maximum
tolerated) HF medication according to current guidelines,
including an angiotensin-converting enzyme inhibitor, a
beta-blocker, and/or spironolactone. Exclusion criteria in-
cluded a recent hospitalization for any major illness 3
months before enrollment into the study; poor treatment
compliance; uncontrolled hypertension or diabetes; clini-
cally significant other illness such as malignancy, unstable
stroke disease, or neurodegenerative illness; and history of
ongoing alcohol or substance abuse.
Study design. Table 1 shows the timeline for the study
design. Patients took part in a 7-day diuretic manipulation
protocol, whereby on day 1 (Tuesday) they received their
usual chronic diuretic dose and omitted diuretic on days 2,
3, and 4. On day 4 (at 72 h), they were given a bolus dose
of intravenous furosemide (50 mg), followed by reinstate-
ment of their usual diuretic on days 5 to 7. Other cardiac
medication was continued as usual. Patients attended the
Abbreviations
and Acronyms
ANP  atrial natriuretic
peptide
BNP  B-type natriuretic
peptide
CV  coefficient of
variation
CVP  central venous
pressure
ELISA  enzyme-linked
immunosorbent assay
GFR  glomerular filtration
rate
HF  heart failure
KIM  kidney injury
molecule
NAG  N-acetyl-beta-
D-glucosaminidase
NGAL  neutrophil
gelatinase-associated
lipocalin
Study DesignTable 1 Study Design
Diuretic Wi
Baseline
1 Tues 14 h 18 h 2 Wed 3
Usual dose of furosemide X
Blood and urine biomarkers X X X XIV  intravenous.study center on days 1, 2, 3, 4, and 7 at the same time on
each occasion (between 7:00 AM and 8:30 AM). Patients
fasted from 9:00 PM the prior evening and refrained from
lcohol, caffeine, and smoking. However, they were allowed
ormal fluid intake to avoid dehydration. On arrival to the
tudy center, they rested supine for 30 min before bladder
oiding and blood collection for biomarker analyses. A total
f 20 ml of blood was collected and transferred into chilled
ubes containing ethylenediaminetetraacetic acid (1.5 mg/
l) and aprotinin (500 IU/ml, Trasylol, Bayer, Newbury,
erks, United Kingdom) and serum separator tubes at room
emperature. Both serum and ethylenediaminetetraacetic
cid/aprotinin tubes were centrifuged at 4°C at 1,200 rpm
or 20 min. Samples were aliquoted into respective plastic
ubes and stored at 70°C for subsequent analyses. Urine
amples were also stored in plastic tubes at 70°C.
amples were gently thawed and vortexed before analysis.
atients underwent daily symptom review and physical
xamination during the diuretic withdrawal phase to
nsure that there were no signs of acute decompensation.
o ensure further patient safety, one of the investigators
M.J.N.K.C.) was available by telephone 24 h per day for
ny emergencies. In case of suspected decompensation,
atients would be admitted to the acute cardiology ward
or treatment and/or observation under the care of the
ttending consultant. All patients gave informed consent,
nd the study was approved by the Local Research and
thics Committee (West-Birmingham).
trial and B-type natriuretic peptide. Atrial natriuretic
eptide (ANP) and B-type natriuretic peptide (BNP) were
sed to track changes in volume status leading to changes in
trial and ventricular stretch, respectively, in response to
olume and pressure changes (11). Both ANP and BNP
ave shorter half-lives, and thus greater observed variability
ver time, than their respective inactive forms, N-terminal
roANP and N-terminal proBNP. Furthermore, although
NP is the more widely studied biomarker in patients with
F, ANP may be more sensitive to acute volume changes
12). ANP was analyzed by enzyme-linked immunosorbent
ssay (ELISA, USCN Life Science Inc., Wuhan, China) at
t. George’s Hospital. The detection limit was 0.14 pg/ml,
ntra-assay coefficient of variation (CV) was 5%, and
nterassay CV was 14%. The assay range was 0 to 25
g/ml, with the normal range being 10 to 70 pg/ml. BNP
as measured using the ADVIA Centaur automated
hemiluminescence system (Siemens Medical Solutions Di-
gnostics, Newbury, Berks, United Kingdom). The interas-
al Diuretic Resumption
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May 31, 2011:2233–41 Volume Status, Diuretics, and Tubular Functionsay CV was 13.6% for low (4.26 pg/ml), 10.0% for medium
(36.9 pg/ml), and 11.2% for high (133.0 pg/ml) values. The
interassay CV was 22.3% for low, 10.9% for medium, and
11.6% for high values. The sensitivity of the assay was 6.9
pg/ml, and the upper detection limit was 17,301 pg/ml.
Urinalysis and markers of tubular damage. Urinary cre-
atinine was determined to correct for concentration of urine.
Neutrophil gelatinase–associated lipocalin (NGAL) was
determined by means of a commercially available ELISA
test kit from Antibody Shop (Gentofte, Denmark). Samples
were diluted 500 times in dilution buffer supplied with the
test kit. The NGAL was first expressed in nanograms per
milliliter (limit of detection 0.093 ng/ml), and values were
then corrected for urinary creatinine concentration. The
enzyme N-acetyl-beta-D-glucosaminidase (NAG) was
evaluated using the substrate p-nitrophenyl N-acetyl--D-
glucosaminide (Sigma, St. Louis, Missouri) in citrate buffer
at pH 4.5. After 60 min at 37°C, 1 M of Na2CO3 was added
to the mixture to terminate the reaction and to develop a
yellow color released from the converted substrate. Controls
were obtained from each sample by addition of Na2CO3 at
time 0. The color was measured at 405 nm by a microtiter
late reader, and controls were subtracted. A standard curve
as made with N-acetyl--D-glucosaminidase. Urinary
NAG activity was first expressed as units per milliliter (limit
of detection 0.113 U/ml) and then adjusted for urinary
creatinine (units per gram of creatinine). Urinary kidney
injury molecule (KIM)-1 measurements were performed
using ELISA (R&D Systems, Minneapolis, Minnesota).
For measurements, 50 l of urine samples were analyzed in
uplicate. The lowest limit of detection for this assay is
.125 ng/ml. The interassay and intra-assay variability was
20%. The urinary KIM-1 level was normalized to the
rinary creatinine concentration (in nanograms per gram of
reatinine).
tatistical analysis. Data are given as mean  SD when
ormally distributed, as median (interquartile range) when
kewed distributed, and as frequencies and percentages for
ategorical variables. Multiple repeated measurement test-
ng was carried out using the Friedman test for non-
ormally distributed variables and the repeated measured
nalysis of variance for normally distributed variables, where
ppropriate. Differences were subsequently determined us-
ng the Wilcoxon signed-rank test for non-normally distrib-
ted variables and the paired-samples t test for normally
istributed variables, where appropriate. All reported prob-
bility values are 2-tailed, and a p value 0.05 was consid-
red statistically significant. Statistical analyses were per-
ormed using SPSS (version 12.0, SPSS Inc., Chicago,
llinois) and STATA (version 10.0, STATA Corp., College
tation, Texas).
esults
total of 30 patients were included in the present study.
able 2 shows the baseline characteristics. The majority ofhe patients were male, with a mean age of 70  7 years.
The main cause of systolic HF was coronary artery disease,
accounting for two thirds of all patients. All patients were
on either ACE inhibitor or angiotensin receptor blocker
therapy. Markers of glomerular and tubular function were
increased in this cohort of patients with HF. Serum creat-
inine was 1.66 (1.32 to 2.28) mg/dl, and mean estimated
glomerular filtration rate (GFR) was 47 (27 to 54) ml/min/
1.73 m2. Urinary KIM-1 at 562 (132 to 1,357) ng/gCr
(normal value 200 ng/gCr), urinary NAG at 8.5 (5.8 to
13.4) U/gCr (normal value 3 U/gCr), and serum NGAL
at 470 (333 to 599) ng/ml (normal 20 ng/ml) were also
increased. Median urinary NGAL levels at 1.4 (0.5 to 26)
g/gCr (normal 60 g/gCr) were not elevated in the
overall study population and were undetectable in 2 of 30
patients.
Effect of diuretic withdrawal. All patients tolerated the
3-day diuretic withdrawal protocol, and none of the patients
experienced an episode of cardiac decompensation. During
Baseline Characteristics of the Study PopulationTable 2 Baseline Characteristics of the Study Population
Age, yrs 70 7
Male 26 (87)
LVEF, % 25 8
NYHA functional class, % (I/II/III) 3/87/10
Systolic blood pressure, mm Hg 136 22
Diastolic blood pressure, mm Hg 77 12
Etiology of heart failure
Ischemic 20 (67)
Idiopathic 5 (17)
Other 5 (17)
eGFR, ml/min/1.73 m2 46 (27–54)
BNP, pg/ml 157 (104–292)
ANP, pg/ml 794 (264–2,543)
Hemoglobin, g/dl 9.1 1.2
Tubular markers
Urinary KIM-1, ng/gCr 562 (132–1,357)
Urinary NAG, U/gCr 8.5 (5.8–13.4)
Urinary NGAL, g/gCr 1.4 (0.5–26.0)
Serum NGAL, ng/ml 470 (333–599)
Medication
ACE inhibitors 20 (67)
ARBs 10 (33)
Beta-blockers 23 (77)
Lipid-lowering agents 23 (77)
Loop diuretics 30 (100)
Aldosterone receptor antagonists 10 (33)
Medical history
Diabetes 10 (33)
Hypertension 14 (47)
Atrial fibrillation 11 (37)
Cerebrovascular/peripheral artery disease 3 (3)
Data are mean  SD, n (%), and median (interquartile range).
ACEi  angiotensin converting enzyme inhibitor; ANP  atrial natriuretic peptide; ARB 
ngiotensin receptor blocker; BNP  brain natriuretic peptide; eGFR  estimated glomerular
ltration rate; KIM  kidney injury molecule; LVEF  left ventricular ejection fraction; NAG 
-acetyl-beta-D-glucosaminidase; NGAL neutrophil gelatinase associated lipocalin; NYHA New
ork Heart Association.diuretic withdrawal, both ANP and BNP levels increased
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Volume Status, Diuretics, and Tubular Function May 31, 2011:2233–41(Fig. 1). ANP showed a significant increase as early as 8 h
after the last dose of oral diuretics, whereas BNP was only
elevated at day 4. There was a nonsignificant increase in
body weight during diuretic withdrawal (1.6 kg, p 
0.149). As a positive control, urinary creatinine concentra-
tions increased during diuretic withdrawal, reaching maxi-
mum urinary concentration at day 2 (Fig. 2). In contrast,
median serum creatinine levels did not significantly change
in this period (mean change from baseline to day 4  0.04 
0.91 mg/dl). Of the measured tubular markers, both urinary
KIM-1 and urinary NAG levels rose significantly after
diuretic discontinuation (Fig. 3A). Urinary KIM-1 levels
rose significantly as early as 8 h after the last dosing of oral
diuretics, with the concentration further increasing up until
day 2 when a plateau phase was reached, with persisting
elevation at day 4 (995 [401 to 1,545] ng/gCr,
p  0.001). Urinary NAG levels rose much slower and less
extensively, but showed similar patterns as the urinary
KIM-1 concentrations (day 4: 9.6 [4.8 to 15.5] U/gCr, p 
0.010). In total, 20 (67%) and 17 (57%) of patients showed
an increase at day 4 for KIM-1 and NAG, respectively. In
contrast, neither plasma nor urinary concentrations of
NGAL changed significantly during diuretic withdrawal
(Fig. 3B), which resulted in 14 (47%) and 15 (50%) patients
showing an increase in urinary and serum NGAL at day 4,
respectively. Online Figures 1A and 1B show the mean
changes over time of all tubular markers. Of those patients
Figure 1 Effect of Diuretic Withdrawal and Reinitiation on ANP
Median and interquartile ranges are presented. *p  0.01 versus day 1, baseline
ANP  atrial natriuretic peptide; BNP  B-type natriuretic peptide; i.v.  intravenowho showed an increase in urinary KIM-1 and NAG levelsat day 4, baseline serum creatinine was higher, whereas
hemoglobin levels and mean arterial pressure were signifi-
cantly lower. Estimated GFR showed a trend toward lower
values at baseline in these patients.
Effect of diuretic reinitiation (after 3 days). After the
intravenous furosemide bolus and reinstatement of oral
furosemide therapy, urinary creatinine and plasma BNP
levels returned to their baseline values before the start of the
study. ANP levels further increased after reinitiation of the
diuretic regimen, resulting in a plasma concentration of
1,183 (430 to 2,674) pg/ml at day 7 (p  0.006 for
difference from baseline). In parallel to the finding with
diuretic withdrawal, mean serum creatinine concentrations
did not change after the reinitiation of diuretic therapy
(mean change 0.05 0.80 mg/dl from reinitiation to day 7).
With diuretic reinitiation, both urinary KIM-1 and urinary
NAG levels returned to their baseline values before the
study (Fig. 4A). Similarly to the quick response to diuretic
withdrawal, urinary KIM-1 levels had already decreased
significantly 4 h after furosemide reinstatement. Urinary
NAG concentrations were significantly decreased as com-
pared with the day 4 levels 8 h after continuation of diuretic
therapy. In total, 23 (77%) and 21 patients (70%) experi-
enced a decrease in either KIM-1 or NAG from day 4 to
day 7, respectively. Neither serum nor urinary NGAL levels
were influenced by the reinitiation of diuretic therapy (Fig.
4B), with 15 (50%) and 16 patients (53%) showing a
BNP Levels
0.05 versus day 1, #p  0.05 versus day 4.and
; †p 
us.decrease at day 7 for urinary and serum NGAL, respectively.
2237JACC Vol. 57, No. 22, 2011 Damman et al.
May 31, 2011:2233–41 Volume Status, Diuretics, and Tubular FunctionOnline Figures 2A and 2B show the mean change in tubular
markers from day 4 and forward.
Discussion
In the present study, we found that a subtle volume increase
after diuretic withdrawal in patients with clinically stable
chronic systolic HF, as shown by an early elevation of ANP
and subsequent elevation of BNP, resulted in a significant
increase in urinary levels of the tubular markers KIM-1 and
NAG, but not NGAL. After reinstitution of the oral
diuretic regimen, urinary levels of both markers returned to
their baseline values.
Modulation of volume status and renal function in HF.
In (chronic) HF, reduced renal blood flow is the most
important determinant of the GFR (6,13,14). However, we
and others have recently shown that not only decreased
perfusion is important in determining renal function, but
also increased renal venous congestion as indicated by
increased CVP (5–7). In these cross-sectional studies, CVP
affected GFR, especially when perfusion was already com-
promised. Yet, to date, no study has evaluated the effect of
modulation of volume by diuretic treatment on parameters
of renal function in patients with systolic HF.
Indirect evidence suggests, however, that changes in
volume status may change renal function. In early experi-
mental studies, induction of increased renal venous pressure
resulted in impairment of renal function (15). Recently,
Mullens et al. (16) showed that decreasing CVP by decreas-
ing intra-abdominal pressure improves renal function. On
Figure 2 Effect of Diuretic Withdrawal and Reinitiation on Seru
Mean  SEM are presented. *p  0.001 versus day 1, baseline; †p  0.05 versthe other hand, in the UNLOAD (Ultrafiltration versus IVDiuretics for Patients Hospitalized for Acute Decompen-
sated Congestive Heart Failure) trial, fluid removal by
ultrafiltration did not result in significant changes in renal
function in patients with acute HF (17).
In our present study, we found that during withdrawal of
diuretics, there was a subtle increase in both ANP and BNP,
as well as a nonsignificant increase in weight, which may
suggest a small increment in CVP. However, the accompa-
nied change in serum creatinine was negligible. On the
other hand, the change in serum creatinine showed a
bell-shaped frequency curve, suggesting that individual
patients may react differently to changes in CVP. Some
patients may be characterized by an asymptomatic intravas-
cular dehydratic state, whereas others may be euvolemic or
even volume-expanded, all without overt decompensation or
symptoms. Nevertheless, serum creatinine may not be the
most accurate and sensitive parameter for early changes in
renal function, as the full effect on serum creatinine may
only occur hours or even days after the initiation of renal
damage (10).
Markers of tubular dysfunction. Tubular markers might
be able to detect changes in renal function earlier than
serum creatinine. Diuretic withdrawal resulted in an
increase in urinary KIM-1 as early as 4 h after the last
oral dose of chronic diuretic therapy, which persisted
after 72 h of diuretic withdrawal. Urinary NAG levels
showed a similar pattern, but the increase was only
apparent after 48 h. Both markers showed a significant
decrease to baseline levels when diuretic therapy was
d Urinary Creatinine Concentrations
4; i.v.  intravenous.m an
us dayreinitiated. Indeed, BNP concentrations decreased to
2238 Damman et al. JACC Vol. 57, No. 22, 2011
Volume Status, Diuretics, and Tubular Function May 31, 2011:2233–41their baseline values after diuretic reinitiation, which may
suggest that a decrease in CVP accompanied the reiniti-
ation of diuretics and the fall in both BNP and urinary
KIM-1/NAG. We also found that patients with compro-
mised kidney function, lower hemoglobin levels, and
lower blood pressures at baseline were especially at
increased risk for deteriorating tubular function. This
group of patients may be more susceptible to volume/
Figure 3 Effect of Diuretic Withdrawal on Urinary KIM-1 and NA
(A) Urinary kidney injury molecule (KIM)-1 and N-acetyl-beta-D-glucosaminidase (NA
day 1, baseline. (B) Serum and urinary neutrophil gelatinase associated lipocalindiuretic changes that can alter renal perfusion and oxygendelivery and may have limited reserve capacity to preserve
tubular function.
These tubular markers are sensitive and are known to
respond extremely quickly after induction of tubular dys-
function or the occurrence of acute kidney injury (10,18,19).
We recently showed that the concentrations of these mark-
ers were increased in congestive heart failure, which may
suggest that this patient group also suffers from chronic
d Serum and Urinary NGAL
edian and interquartile ranges are presented. *p  0.01; †p  0.075 versus
). Median and interquartile ranges are presented.G an
G). M
(NGALhypoxic tubular damage in addition to reduced glomerular
2239JACC Vol. 57, No. 22, 2011 Damman et al.
May 31, 2011:2233–41 Volume Status, Diuretics, and Tubular Functionfunction (20). KIM-1 is thought to be expressed in the urine
when (hypoxic) tubular dysfunction develops, whereas the
response time of urinary NAG is somewhat slower and less
specific (21,22). The absence of any alteration in NGAL
levels in urine or serum remains obscure. NGAL levels may
not only be dependent of tubular dysfunction, but also of
other comorbid organ dysfunction and inflammation (23).
Figure 4 Effect of Diuretic Reinitiation on Urinary KIM-1 and NA
(A) Urinary KIM-1 and NAG. Median and interquartile ranges are presented. *p 
Median and interquartile ranges are presented. i.v.  intravenous; other abbreviatFurthermore, urinary NGAL levels are more dependent onproduction of NGAL in the distal tubule after injury,
whereas both KIM-1 and NAG are markers that represent
proximal tubular injury (23). Although proximal tubular
injury may also result in higher urinary NGAL levels, this is
a reflection of serum NGAL that has been filtered through
the glomerulus and not reabsorbed in the proximal tubule.
Given the absence of changes in serum NGAL, this may be
d Urinary and Plasma NGAL
ersus day 4, 0 h. (B) Urinary and plasma NGAL.
s in Figure 3.G an
0.05 v
ions aa reason for a lack of an effect on NGAL. Together, this
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Volume Status, Diuretics, and Tubular Function May 31, 2011:2233–41may suggest that especially proximal tubular injury occurs
(rise in KIM-1 and NAG), whereas distal tubular injury is
limited (no effect on NGAL). Finally, it is possible that
NGAL may not be susceptible to changes in volume status,
but more to substantial changes in renal perfusion. The
present study does not allow us to investigate this.
Direct effects of diuretics. The effects of diuretics on renal
function might not only be related to changes in CVP, but
diuretics might have a direct effect on renal function as well.
Diuretic therapy has been indirectly related to worsening
renal function. Gottlieb et al. (24) showed that although
urosemide is a well-known and potent natriuretic agent, it
lso induces a significant fall in GFR. This impact on renal
unction may be greater in patients with systolic HF. More
ecently, Metra et al. (4) found that patients who receive
igher dosing of diuretics were especially at risk for devel-
pment of worsening renal function. In addition, via the
ubuloglomerular feedback mechanism, higher sodium con-
entrations in the distal tubules may trigger afferent vaso-
onstriction, inducing reduced GFR (25).
Only a few studies have previously explored the impact of
rogrammed diuretic withdrawal in patients with systolic
F. One small study showed that diuretic withdrawal in 4
atients with HF implanted with a hemodynamic monitor
ed to individual changes in hemodynamics, with high
nterindividual variability (26). Galve et al. (27) showed that
ith diuretic withdrawal, renal function parameters im-
roved after 3 months of withdrawal. However, no previous
tudy has evaluated the short-term effect of diuretic with-
rawal on renal function parameters or the effect of reiniti-
tion of diuretic therapy.
In our present study, diuretic withdrawal led to increased
oncentrations of markers of tubular dysfunction, an effect
hat was attenuated by the reinitiation of diuretic therapy.
oop diuretics have been shown to preferentially improve
edullary but not cortical oxygen tension (28). In addition,
urosemide treatment leads to reduced renal oxygen con-
umption in patients admitted to the intensive care unit
fter cardiac surgery (29). Therefore, diuretics may improve
edullar oxygen tensions by decreasing the need for sodium
nd water retention in this region of the kidney, resulting in
mproved oxygen availability. Considering the extreme salt-
etaining state in patients with systolic HF, this may be an
mportant mechanism to prevent hypoxic tubular damage.
mplications. Our results suggest that loop diuretic ther-
py may favorably affect makers of tubular function in HF
atients with a presumed euvolemic state. Whether this is
ue to changes in volume status or a more direct effect is
nclear. However, our findings may suggest a balance
etween diuretic use, volume status, and renal function.
ach of these factors will be subject to variations that may
isturb this balance, which consequently may trigger further
lterations by a treating physician. This could be either
ithdrawing or (re)initiating diuretics, depending on the
linical characteristics. However, we have shown that some
ubular markers may give important information on theourse of renal and tubular function during these adjust-
ents in therapy. Although some evidence suggests that
aggressive) loop diuretic therapy may increase mortality
nd renal insufficiency, our present short-term data suggest
hat, at least in some patients, this seems not to be the case
9). Our results further underline the need for individualized
edicine and the need for more research on the interaction
etween diuretics, volume status, and renal function in
atients with HF.
tudy limitations. The patient population consisted of
atients in an approximate euvolemic state, which was
ssessed largely on the basis of symptomatic stability,
linical examination, and echocardiography. Median base-
ine BNP levels were not extremely elevated, supporting
hese assessments. However, it should be noted and would
e expected that the results would have been different in
atients with pronounced hypervolemia or perhaps even
ore rigorous hypovolemia. We used ANP and BNP as
arkers of filling pressures, but we did not assess CVP or
enal venous pressure directly. We observed a sustained
levation in ANP levels, even after reinitiation of diuretics.
ecause ANP is a strong marker of hypervolemia, it would
ave been expected to decrease with volume depletion.
owever, from our study we cannot derive an explanation
or this unexpected finding. During our study, protein and
odium intake was not tightly controlled, which could be a
ource of bias in our analyses. Although our study was
ightly controlled within subjects, it consisted of a limited
umber of patients and should be replicated in a larger
tudy. It must be noted, however, that the sequential
easurements (before, during, and after withdrawal of
iuretics) of renal function and tubular markers is an
mportant strength of our study.
onclusions
ur present results indicate that subtle changes in volume
tatus by modulation of diuretic therapy lead to parallel
hanges in markers of tubular dysfunction in patients with
ystolic HF. Diuretic therapy may favorably affect tubular
unction by decreasing congestion or a direct pharmacolog-
cal effect. Withdrawal of diuretic therapy in stable patients
ay be associated with recordable rises in biomarkers of
enal injury.
Acknowledgment
The authors thank Jeetesh Patel, PhD, from the University
Department of Medicine, Birmingham, for his support with
the BNP analyses.
Reprint requests and correspondence: Dr. Kevin Damman,
Department of Cardiology, University Medical Center Groningen,
Hanzeplein 1, 9700RB Groningen, the Netherlands. E-mail:
k.damman@thorax.umcg.nl.
2241JACC Vol. 57, No. 22, 2011 Damman et al.
May 31, 2011:2233–41 Volume Status, Diuretics, and Tubular FunctionREFERENCES
1. Hillege HL, Girbes AR, de Kam PJ, et al. Renal function, neurohor-
monal activation, and survival in patients with chronic heart failure.
Circulation 2000;102:203–10.
2. Damman K, Jaarsma T, Voors AA, Navis G, Hillege HL, van
Veldhuisen DJ. Both in- and out-hospital worsening of renal function
predict outcome in patients with heart failure: results from the
Coordinating Study Evaluating Outcome of Advising and Counseling
in Heart Failure (COACH). Eur J Heart Fail 2009;11:847–54.
3. Damman K, Navis G, Voors AA, et al. Worsening renal function and
prognosis in heart failure: systematic review and meta-analysis. J Card
Fail 2007;13:599–608.
4. Metra M, Nodari S, Parrinello G, et al. Worsening renal function in
patients hospitalised for acute heart failure: clinical implications and
prognostic significance. Eur J Heart Fail 2008;10:188–95.
5. Damman K, van Deursen VM, Navis G, Voors AA, van Veldhuisen
DJ, Hillege HL. Increased central venous pressure is associated with
impaired renal function and mortality in a broad spectrum of patients
with cardiovascular disease. J Am Coll Cardiol 2009;53:582–8.
6. Damman K, Navis G, Smilde TD, et al. Decreased cardiac output,
venous congestion and the association with renal impairment in
patients with cardiac dysfunction. Eur J Heart Fail 2007;9:872–8.
7. Mullens W, Abrahams Z, Francis GS, et al. Importance of venous
congestion for worsening of renal function in advanced decompensated
heart failure. J Am Coll Cardiol 2009;53:589–96.
8. Ng Kam Chuen MJ, Lip GY, Macfadyen RJ. Performing repeated
noninvasive bedside measures of volume response to intravenous
furosemide in acute pulmonary edema: a feasibility assessment. Car-
diovasc Ther 2009;27:89–95.
9. Domanski M, Norman J, Pitt B, Haigney M, Hanlon S, Peyster E.
Diuretic use, progressive heart failure, and death in patients in the
Studies Of Left Ventricular Dysfunction (SOLVD). J Am Coll
Cardiol 2003;42:705–8.
10. Mishra J, Dent C, Tarabishi R, et al. Neutrophil gelatinase-associated
lipocalin (NGAL) as a biomarker for acute renal injury after cardiac
surgery. Lancet 2005;365:1231–8.
11. Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol
2007;50:2357–68.
12. Larsen AI, Dickstein K, Ahmadi NS, Aarsland T, Kvaloy JT, Hall C.
The effect of altering haemodynamics on the plasma concentrations of
natriuretic peptides in heart failure. Eur J Heart Fail 2006;8:628–33.
13. Ljungman S, Laragh JH, Cody RJ. Role of the kidney in congestive
heart-failure: relationship of cardiac index to kidney function. Drugs
1990;39:10–21.
14. Smilde TD, Damman K, van der Harst P, et al. Differential associa-
tions between renal function and “modifiable” risk factors in patients
with chronic heart failure. Clin Res Cardiol 2009;98:121–9.
15. Maxwell MH, Breed ES, Schwartz IL. Renal venous pressure in
chronic congestive heart failure. J Clin Invest 1950;29:342–8.16. Mullens W, Abrahams Z, Francis GS, Taylor DO, Starling RC, Tang
WH. Prompt reduction in intra-abdominal pressure following large-
volume mechanical fluid removal improves renal insufficiency in
refractory decompensated heart failure. J Card Fail 2008;14:508–14.
17. Costanzo MR, Saltzberg M, O’Sullivan J, Sobotka P. Early ultrafil-
tration in patients with decompensated heart failure and diuretic
resistance. J Am Coll Cardiol 2005;46:2047–51.
18. Vaidya VS, Ramirez V, Ichimura T, Bobadilla NA, Bonventre JV.
Urinary kidney injury molecule-1: a sensitive quantitative biomarker
for early detection of kidney tubular injury. Am J Physiol Renal Physiol
2006;290:F517–29.
19. Wellwood JM, Ellis BG, Price RG, Hammond K, Thompson AE,
Jones NF. Urinary N-acetyl- beta-D-glucosaminidase activities in
patients with renal disease. Br Med J 1975;3:408–11.
20. Damman K, van Veldhuisen DJ, Navis G, Voors AA, Hillege HL.
Urinary neutrophil gelatinase associated lipocalin (NGAL), a marker
of tubular damage, is increased in patients with chronic heart failure.
Eur J Heart Fail 2008;10:997–1000.
21. Vaidya VS, Ferguson MA, Bonventre JV. Biomarkers of acute kidney
injury. Annu Rev Pharmacol Toxicol 2008;48:463–93.
22. Waikar SS, Bonventre JV. Biomarkers for the diagnosis of acute
kidney injury. Curr Opin Nephrol Hypertens 2007;16:557–64.
23. Schmidt-Ott KM, Mori K, Li JY, et al. Dual action of neutrophil
gelatinase-associated lipocalin. J Am Soc Nephrol 2007;18:407–13.
24. Gottlieb SS, Skettino SL, Wolff A, et al. Effects of BG9719 (CVT-
124), an A1-adenosine receptor antagonist, and furosemide on glo-
merular filtration rate and natriuresis in patients with congestive heart
failure. J Am Coll Cardiol 2000;35:56–9.
25. Vallon V, Miracle C, Thomson S. Adenosine and kidney function:
potential implications in patients with heart failure. Eur J Heart Fail
2008;10:176–87.
26. Braunschweig F, Linde C, Eriksson MJ, Hofman-Bang C, Ryden L.
Continuous haemodynamic monitoring during withdrawal of diuretics
in patients with congestive heart failure. Eur Heart J 2002;23:59–69.
27. Galve E, Mallol A, Catalan R, et al. Clinical and neurohumoral
consequences of diuretic withdrawal in patients with chronic, stabi-
lized heart failure and systolic dysfunction. Eur J Heart Fail 2005;7:
892–8.
28. Brezis M, Agmon Y, Epstein FH. Determinants of intrarenal oxygen-
ation. I. Effects of diuretics. Am J Physiol 1994;267:F1059–F1062.
29. Sward K, Valsson F, Sellgren J, Ricksten SE. Differential effects of
human atrial natriuretic peptide and furosemide on glomerular filtra-
tion rate and renal oxygen consumption in humans. Intensive Care
Med 2005;31:79–85.
Key Words: diuretics y heart failure y kidney y tubular damage.
APPENDIXFor supplementary figures, please see the online version of this article.
